Zachary Hunzeker

POSTER: CT-1677: Extranodal Involvement and Hepatobiliary Dysfunction as Determinants of Outcomes After CAR T-Cell Therapy

Zachary Hunzeker, James Hill, Chiara Hummel, Sami Khaznadar et autres

us (code pays fourni par la source)

CT-1677: Extranodal Involvement and Hepatobiliary Dysfunction as Determinants of Outcomes After CAR T-Cell Therapy

Zachary Hunzeker, James Hill, Chiara Hummel, Sami Khaznadar et autres

us (code pays fourni par la source)

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya et autres

us (code pays fourni par la source)

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Hector Garcia Pleitez, Oren Pasvolsky, Lei Feng, Mahmoud Gaballa et autres

Abstract Introduction: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory multiple myeloma (RRMM) have shown deep and durable responses. However, real-world data on early CAR T-cell expansion dynamics and its association with treatment-related toxicities remain incomplete. This study …

us (code pays fourni par la source)

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Rahul K. Shah, Xiaowen Sun, Lei Feng, Anath C. Lionel et autres

Abstract Background Anakinra, an IL-1 receptor antagonist approved for rheumatologic conditions, has been increasingly used off-label as a corticosteroid-sparing agent for refractory cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor T-cell therapy (CART). Preclinical models …

us (code pays fourni par la source)

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Anath C. Lionel, Sushanth Gouni, Karan Chohan, Lei Feng et autres

Abstract Background: Lymphomatous involvement of extranodal (EN) sites has been recognized as a negative prognostic factor for patients (pts) treated with chemoimmunotherapy and has been incorporated into risk stratification scores such as the IPI for large B-cell lymphoma (LBCL) and FLIPI2 for …

us (code pays fourni par la source)

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Christen Dillard, Ruchi Singhal, Oren Pasvolsky, Chijioke Nze et autres

Abstract INTRODUCTION Bispecific antibodies represent a transformative therapy for relapsed/refractory multiple myeloma (RRMM). Teclistamab, the first FDA-approved B-cell maturation antigen (BCMA)-directed bispecific antibody, has demonstrated efficacy in clinical trials, but real-world outcomes may vary due to differences in baseline characteristics, treatment history, …

us (code pays fourni par la source)

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark P. Hamilton, Ajlan Al Zaki, Lei Feng, Zachary Hunzeker et autres

Abstract Introduction. Approximately 30% of patients with large B-cell lymphoma (LBCL) achieve a partial response (PR) after CAR T-cell therapy (CART). While about 70% of PR patients will progress, there is no standard consolidation strategy for these patients, who are typically only …

us (code pays fourni par la source)

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Zachary Hunzeker, Anath C. Lionel, Xiaowen Sun, Lei Feng et autres

Abstract Background: Peripherally inserted central catheter (PICC) is the most commonly utilized central venous access for chimeric antigen receptor T-cell therapy (CART) infusion, due to hypothetical concern that the angled needle of a Port may enact shear stress on CAR T-cells. However, …

us (code pays fourni par la source)

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Danai Dima, Lauren C. Peres, Leyla Shune, Brett M. Reid et autres

Abstract Introduction Cilta-cel is a BCMA-directed CAR T-cell therapy that has shown remarkable efficacy in patients with RRMM. As real-world (RW) experience with cilta-cel continues to expand, and with the recent FDA guidance reducing the recommended proximity to the CAR T center …

us, ch (code pays fourni par la source)

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Paolo Strati, Lei Feng, Luis Malpica, Ranjit Nair et autres

Abstract Introduction . We have recently completed a phase I trial of evorpacept (formerly known as ALX148), a novel high-affinity signal regulatory protein (SIRP)a fusion protein that blocks cluster of differentiation (CD)47, in combination with lenalidomide and rituximab (R2) in patients with …

us (code pays fourni par la source)

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Kunhwa Kim, Zhouxuan Li, Wei Qiao, Amy Ayers et autres

Abstract Background: Currently approved in the third-line or later settings, anti-CD3xCD20 bispecific antibodies (BsAb) are increasingly utilized in the treatment of large B-cell lymphoma (LBCL). These therapies harness CD3+ T cells for anti-tumor activity by recruiting and activating them to target CD20-expressing …

us (code pays fourni par la source)